Materials of the Expert Council “Ornithine in Oncological Practice”
S. V. Okovityi,
M. Yu. Nadinskaia,
M. V. Maevskaya,
O. A. Gladkov,
E. E. Vasenina,
V. R. Grechishnikova,
T. A. Deeva,
M. S. Zharkova,
M. F. Osipenko,
M. K. Prashnova,
V. A. Prikhodko,
K. L. Raikhelson https://doi.org/10.21518/ms2025-237
Abstract
Among chemotherapy-related adverse events, drug-induced liver injury (DILI) is one of the most prevalent. In some cases, DILI is accompanied by hyperammonaemia (HA), which can disrupt chemotherapy cycles, and is associated with 25–45% mortality rates when specific antitumor agents are used. Efficacy studies in cancer patients were only found for ornithine (L-ornithine L-aspartate, LOLA) among all ammonia-lowering strategies. The amino acids in LOLA help to detoxify ammonia in the liver and other tissues, while also having several other metabolic effects. The experts expressed their viewpoints on the conducted studies, reviewed the main directions for applying LOLA in current clinical practice, and identified prospects for further research.
About the Authors
S. V. Okovityi
Санкт-Петербургский государственный химико-фармацевтический университет;
Санкт-Петербургский государственный университет
Russian Federation
Russian Federation
Sergey V. Okovityi
M. Yu. Nadinskaia
Первый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)
Russian Federation
Russian Federation
Maria Yu. Nadinskaia
M. V. Maevskaya
Первый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)
Russian Federation
Russian Federation
Marina V. Maevskaya
O. A. Gladkov
Медицинский центр «Эвимед»
Russian Federation
Russian Federation
Oleg A. Gladkov
E. E. Vasenina
Российская медицинская академия непрерывного профессионального образования
Russian Federation
Russian Federation
Elena E. Vasenina
V. R. Grechishnikova
Первый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)
Russian Federation
Russian Federation
Vasilisa R. Grechishnikova
T. A. Deeva
Первый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)
Russian Federation
Russian Federation
Tatiana A. Deeva
M. S. Zharkova
Первый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)
Russian Federation
Russian Federation
Maria S. Zharkova
M. F. Osipenko
Новосибирский государственный медицинский университет
Russian Federation
Russian Federation
Marina F. Osipenko
M. K. Prashnova
Санкт-Петербургский государственный университет
Russian Federation
Russian Federation
Mariya K. Prashnova,
V. A. Prikhodko
Санкт-Петербургский государственный химико-фармацевтический университет
Russian Federation
Russian Federation
Veronika A. Prikhodko
K. L. Raikhelson
Санкт-Петербургский государственный университет;
Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова
Russian Federation
Russian Federation
Karina L. Raikhelson
References
1. Mitani S, Kadowaki S, Komori A, Sugiyama K, Narita Y, Taniguchi H et al. Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy: A case series and review of the literature. Medicine. 2017;96(22):e6874. https://doi.org/10.1097/MD.0000000000006874.
2. Balcerac A, Bihan K, Lebrun-Vignes B, Thabut D, Salem JE, Weiss N. Drugassociated hyperammonaemia: a Bayesian analysis of the WHO Pharmacovigilance Database. Ann Intensive Care. 2022;12(1):55. https://doi.org/10.1186/s13613-022-01026-4.
3. Oura M, Oguro F, Agatsuma N, Imamaki H, Nishikawa Y. Fluoropyrimidine usage in cases with hyperammonemia: real-world data study using the Japanese Adverse Drug Event Report (JADER) database. Cancer Chemother Pharmacol. 2023;92(1):7–14. https://doi.org/10.1007/s00280-023-04542-7.
4. Stock W, Douer D, DeAngelo DJ, Arellano M, Advani A, Damon L et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011;52(12):2237–2253. https://doi.org/10.3109/10428194.2011.596963.
5. Chu G, Salzman J. Hyperammonemia after capecitabine associated with occult impairment of the urea cycle. Cancer Med. 2019;8(5):1996–2004. https://doi.org/10.1002/cam4.2036.
6. Shakerdi L, Ryan A. Drug-induced hyperammonaemia. J Clin Pathol. 2023;76(8):501–509. https://doi.org/10.1136/jcp-2022-208644.
7. Tokuyama N, Ikeda S, Ishida R, Futai R, Tobimatsu K, Kodama Y. Impaired Consciousness Due to Hyperammonemia During S-1 Administration for Unresectable Pancreatic Cancer. Intern Med. 2025;64(5):695–698. https://doi.org/10.2169/internalmedicine.3771-24.
8. Hyo Kim L, Sub Cheong H, Koh Y, Ahn KS, Lee C, Kim HL et al. Cytidine deaminase polymorphisms and worse treatment response in normal karyotype AML. J Hum Genet. 2015;60(12):749–754. https://doi.org/10.1038/jhg.2015.105.
9. Gourdier I, Del Rio M, Crabbé L, Candeil L, Copois V, Ychou M et al. Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma. FEBS Lett. 2002;529(2-3):232–236. https://doi.org/10.1016/s0014-5793(02)03347-1.
10. Nosaka K, Nakada J, Endou H. Cisplatin-induced alterations in renal structure, ammoniagenesis and gluconeogenesis of rats. Kidney Int. 1992;41(1):73–79. https://doi.org/10.1038/ki.1992.10.
11. Laemmle A, Hahn D, Hu L, Rüfenacht V, Gautschi M, Leibundgut K et al. Fatal hyperammonemia and carbamoyl phosphate synthetase 1 (CPS1) deficiency following high-dose chemotherapy and autologous hematopoietic stem cell transplantation. Mol Genet Metab. 2015;114(3):438–444. https://doi.org/10.1016/j.ymgme.2015.01.002.
12. Lee A, Eldem I, Altintas B, Nguyen H, Willis D, Langley R, Shinawi M. Treatment and outcomes of symptomatic hyperammonemia following asparaginase therapy in children with acute lymphoblastic leukemia. Mol Genet Metab. 2023;139(3):107627. https://doi.org/10.1016/j.ymgme.2023.107627.
13. García-Díaz HC, Eremiev S, Gómez-Alonso J, Veas Rodriguez J, Farriols A, Carreras MJ, Serrano C. Hyperammonemic encephalopathy after tyrosine kinase inhibitors: A literature review and a case example. J Oncol Pharm Pract. 2024;30(3):576–583. https://doi.org/10.1177/10781552231225188.
14. Iriyama N, Miura K, Uchino Y, Takahashi H, Nakagawa M, Iizuka K et al. Relationship between Carnitine Deficiency and Tyrosine Kinase Inhibitor Use in Patients with Chronic Myeloid Leukemia. Chemotherapy. 2022;67(2):96–101. https://doi.org/10.1159/000521113.
15. Chapuy CI, Sahai I, Sharma R, Zhu AX, Kozyreva ON. Hyperammonemic Encephalopathy Associated With Fibrolamellar Hepatocellular Carcinoma: Case Report, Literature Review, and Proposed Treatment Algorithm. Oncologist. 2016;21(4):514–520. https://doi.org/10.1634/theoncologist.2015-0267.
16. Kim GW, Lee DH, Jeon YH, Yoo J, Kim SY, Lee SW et al. Glutamine Synthetase as a Therapeutic Target for Cancer Treatment. Int J Mol Sci. 2021;22(4):1701. https://doi.org/10.3390/ijms22041701.
17. Nadinskaia MYu, Kodzoeva KhB, Gulyaeva KA, Khen ME, Koroleva DI, Privalov MA et al. Risk Factors of Portal Vein Thrombosis in Patients with Different Child-Pugh Classes Liver Cirrhosis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2023;33(2):45–59. (In Russ.) https://doi.org/10.22416/1382-4376-2023-33-2-45-59.
18. Tang J, Yang N, Pan S, Ren P, Chen M, Jin J et al. The renal damage and mechanisms relevant to antitumoral drugs. Front Oncol. 2023;13:1331671. https://doi.org/10.3389/fonc.2023.1331671.
19. Guevara-Ramírez P, Cadena-Ullauri S, Paz-Cruz E, Ruiz-Pozo VA, Tamayo-Trujillo R, Cabrera-Andrade A, Zambrano AK. Gut Microbiota Disruption in Hematologic Cancer Therapy: Molecular Insights and Implications for Treatment Efficacy. Int J Mol Sci. 2024;25(19):10255. https://doi.org/10.3390/ijms251910255.
20. Schäfer TV, Ivnitsky JJ, Rejniuk VL. Cyclophosphamide-induced leakage of gastrointestinal ammonia into the common bloodstream in rats. Drug Chem Toxicol. 2011;34(1):25–31. https://doi.org/10.3109/01480545.2010.483518.
21. Nadinskaia MYu, Maevskaya MV, Bakulin IG, Bessonova EN, Bueverov AO, Zharkova MS et al. Diagnostic and Prognostic Value of Hyperammonemia in Patients with Liver Cirrhosis, Hepatic Encephalopathy, and Sarcopenia (Experts’ Agreement). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(1):85–100. (In Russ.) https://doi.org/10.22416/1382-4376-2024-34-1-85-100.
22. Ganju RG, Morse R, Hoover A, TenNapel M, Lominska CE. The impact of sarcopenia on tolerance of radiation and outcome in patients with head and neck cancer receiving chemoradiation. Radiother Oncol. 2019;137:117–124. https://doi.org/10.1016/j.radonc.2019.04.023.
23. Panje CM, Höng L, Hayoz S, Baracos VE, Herrmann E, Garcia Schüler H et al. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy. Radiat Oncol. 2019;14(1):166. https://doi.org/10.1186/s13014-019-1372-3.
24. Kamarajah SK, Bundred J, Tan BHL. Body composition assessment and sarcopenia in patients with gastric cancer: a systematic review and metaanalysis. Gastric Cancer. 2019;22:10–22. https://doi.org/10.1007/s10120-018-0882-2.
25. Lyadov VK, Fedorinov DS, Statsenko YA, Lyadova MA, Boldyreva TS, Galkin VN. Cachexia and Sarcopenia as Predictive Factors in Patients With Gastric Cancer: Observational Study. Moscow Surgical Journal. 2024;(1):61–69. (In Russ.) Available at: https://www.mossj.ru/jour/article/view/758.
26. Sánchez M, Castro-Eguiluz D, Luvián-Morales J, Jiménez-Lima R, Aguilar-Ponce JL, Isla-Ortiz D, Cetina L. Deterioration of nutritional status of patients with locally advanced cervical cancer during treatment with concomitant chemoradiotherapy. J Hum Nutr Diet. 2019;32(4):480–491. https://doi.org/10.1111/jhn.12649.
27. Chung E, Lee HS, Cho ES, Park EJ, Baik SH, Lee KY, Kang J. Prognostic significance of sarcopenia and skeletal muscle mass change during preoperative chemoradiotherapy in locally advanced rectal cancer. Clin Nutr. 2020;39(3):820–828. https://doi.org/10.1016/j.clnu.2019.03.014.
28. Psutka SP, Carrasco A, Schmit GD, Moynagh MR, Boorjian SA, Frank I et al. Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality. Cancer. 2014;120(18):2910–2918. https://doi.org/10.1002/cncr.28798.
29. Kukosh MYu, Ter-Ovanesov MD. Sarcopenia in oncology practice. Medical Alphabet. 2018;1(15):37–43. (In Russ.) Available at: https://www.medalphabet.com/jour/article/view/637/637.
30. Anjanappa M, Corden M, Green A, Roberts D, Hoskin P, McWilliam A, Choudhury A. Sarcopenia in cancer: Risking more than muscle loss. Tech Innov Patient Support Radiat Oncol. 2020;16:50–57. https://doi.org/10.1016/j.tipsro.2020.10.001.
31. Li S, Wang T, Tong G, Li X, You D, Cong M. Prognostic Impact of Sarcopenia on Clinical Outcomes in Malignancies Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Front Oncol. 2021;11:726257. https://doi.org/10.3389/fonc.2021.726257.
32. Luo L, Shen X, Fang S, Teng Wan, Pan Liu, Peiling Li et al. Sarcopenia as a risk factor of progression-free survival in patients with metastases: a systematic review and meta-analysis. BMC Cancer. 2023;23(1):127. https://doi.org/10.1186/s12885-023-10582-2.
33. Ivashkin VT, Mayevskaya MV, Pavlov ChS, Fedosyina YeA, Bessonova YeN, Pirogova IYu, Garbuzenko DV. Treatment of liver cirrhosis complications: Clinical guidelines of the Russian Scientific Liver Society and Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(4):71–102. (In Russ.) https://doi.org/10.22416/1382-4376-2016-4-71-102.
34. Kleef R, Scheller A. L-ornithine aspartate – a rationale for its use in combination with chemotherapy, radiation, and hyperthermia in oncology. Forsch Komplementarmed. 1999;6(4):216. https://doi.org/10.1159/000021252.
35. Lazebnik LB, Golovanova EV, Alekseenko SA, Bueverov AO, Plotnikova EYu, Dolgushina AI, et al. Russian Consensus “Hyperammonemia in Adults” (Version 2021). Experimental and Clinical Gastroenterology. 2021;(3):97–118. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-187-3-97-118.
36. Ивашкин ВТ, Маевская МВ, Жаркова МС, Жигалова СБ, Киценко ЕА, Манукьян ГВ, Тихонов ИН. Цирроз и фиброз печени: клинические рекомендации. 2021. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/715_1.
37. Nott L, Price TJ, Pittman K, Patterson K, Fletcher J. Hyperammonemia encephalopathy: an important cause of neurological deterioration following chemotherapy. Leuk Lymphoma. 2007;48(9):1702–1711. https://doi.org/10.1080/10428190701509822.
38. Nussbaum V, Lubcke N, Findlay R. Hyperammonemia secondary to asparaginase: A case series. J Oncol Pharm Pract. 2016;22(1):161–164. https://doi.org/10.1177/1078155214551590.
39. Aitkenhead H. UK National audit of the measurement of ammonia. Ann Clin Biochem. 2023;60(2):117–125. https://doi.org/10.1177/00045632231152085.
40. Stepien KM, Geberhiwot T, Hendriksz CJ, Treacy EP. Challenges in diagnosing and managing adult patients with urea cycle disorders. J Inherit Metab Dis. 2019;42(6):1136-1146. https://doi.org/10.1002/jimd.12096.
41. Bélanger-Quintana A, Arrieta Blanco F, Barrio-Carreras D, Bergua Martínez A, Cañedo Villarroya E, García-Silva MT et al. Recommendations for the Diagnosis and Therapeutic Management of Hyperammonaemia in Paediatric and Adult Patients. Nutrients. 2022;14(13):2755. https://doi.org/10.3390/nu14132755.
42. Tseng YL, Huang CR, Lin CH, Lu YT, Lu CH, Chen NC et al. Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy. Medicine. 2014;93(11):e66. https://doi.org/10.1097/MD.0000000000000066.
43. Scheller A, Jacob U, Keilhauer R, et al. Verbesserung der Zytostatikatoleranz durch Ornithinaspartat [Improvement of cytostatic tolerance by ornithine aspartate]. Der Bayrische Internist. 1998;(1):54–60. (In German).
44. Larionova VB, Gorozhanskaya EG. Prospects for using Hepa-Merz (L-ornithine-L-aspartate) for the prevention and treatment of drug-induced liver damage. Effective Pharmacotherapy. 2009;(3):6–15. (In Russ.) Available at: https://umedp.ru/articles/perspektivy_primeneniya_gepamerts_lornitinlaspartat_dlya_profilaktiki_i_lecheniya_lekarstvennogo_por.html.
45. Matsyshevskaya IV. Experience for the use of Ornitoks (L-ornithine-Laspartate) in practice of department chemotherapy of regional Vinnitsry clinical oncological center for chemotherapy. Klinicheskaya Onkologiya. 2011;4(4):1–3. (In Russ.) Available at: https://www.clinicaloncology.com.ua/wp/wp-content/uploads/2011/12/61.pdf.
46. Maksimova EV, Kliaritskaia IL. Hepatic encephalopathy, diagnostics, differential diagnostics and therapy with ornithine. Consilium Medicum. 2018;20(12):110–116. (In Russ.) Available at: https://consilium.orscience.ru/2075-1753/article/view/95148.
47. Skrypnyk IM, Maslova GS, Skrypnyk RI. Effects of L-ornithine-L-aspartate on the manifestation of minimal hepatic encephalopathy in the dynamics of cytostatic therapy. Modern Gastroenterology. 2018;6(104):29–34. https://doi.org/10.30978/MG-2018-6-29.
48. Maslova GS, Skrypnyk RI, Skrypnyk IN. The role of L-ornithine-L-aspartate in prophylaxis of cytostatic-induced liver injury in patients with multiple myeloma. World Med Biol. 2021;17(78):100–104. https://doi.org/10.26724/2079-8334-2021-4-78-100-104.
49. Soldatova GS, Pospelova TI, Checherina AA. Hyperammonemia in patients with lymphoproliferative diseases. Gematologiya i Transfuziologiya. 2022;67(2 Suppl.):300–301. (In Russ.) Available at: https://www.htjournal.ru/jour/article/view/396/282.
50. Charniakova LK, Surmach KM, Malkin MR. Therapeutic efficacy of L-ornithineL-aspartate in palliative care patients. Meditsinskie Novosti. 2023;(6):50–51. (In Russ.) Available at: https://www.mednovosti.by/journal.aspx?article=9915.
51. Bryshtel MV. Use of the drug L-ornithine-L-aspartate (Hepa-Merz) for the treatment of hepatotoxicity in the treatment of malignant neoplasms. Meditsinskie Novosti. 2024;(3):68–70. (In Russ.) Available at: https://www.mednovosti.by/journal.aspx?article=10089.
52. Butterworth RF, Canbay A. Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease. Dig Dis. 2019;37(1):63–68. https://doi.org/10.1159/000491429.
53. Canbay A, Sowa JP. L-Ornithine L-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver Disease. Drugs. 2019;79(Suppl. 1):39–44. https://doi.org/10.1007/s40265-018-1020-5.
54. Reynolds N, Downie S, Smith K, Kircheis G, Rennie MJ. Treatment with L-ornithine aspartate (LOLA) infusion restores muscle protein synthethis responsiveness to feeding in patients with cirrhosis. J Hepatol. 1999;30(Suppl. 1):1999. Available at: https://eurekamag.com/research/035/984/035984326.php.
55. Pasha Y, Taylor-Robinson S, Leech R, Ribeiro I, Cook N, Crossey M, Marcinkowski H. PWE-091 L-ornithine L-aspartate in minimal hepatic encephalopathy: possible effects on the brain-muscle axis? Gut. 2018;67(Suppl. 1):A117-A118. https://doi.org/10.1136/gutjnl-2018-BSGAbstracts.233.
56. Ostrovskaya AS, Maevskaya MV, Loban KM, Zharkova MS, Shapka MP, Nadinskaia MY et al. Upper limb SMI for sarcopenia diagnosis in liver cirrhosis. Meditsinskiy Sovet. 2024;18(15):126–134. (In Russ.) https://doi.org/10.21518/ms2024-382.
57. Sugino T, Shirai T, Kajimoto Y, Kajimoto O. L-ornithine supplementation attenuates physical fatigue in healthy volunteers by modulating lipid and amino acid metabolism. Nutr Res. 2008;28(11):738–743. https://doi.org/10.1016/j.nutres.2008.08.008.
58. Holecek M. Relation between glutamine, branched-chain amino acids, and protein metabolism. Nutrition. 2002;18(2):130–133. https://doi.org/10.1016/s0899-9007(01)00767-5.
59. Butterworth RF. L-Ornithine L-Aspartate for the Treatment of Sarcopenia in Chronic Liver Disease: The Taming of a Vicious Cycle. Can J Gastroenterol Hepatol. 2019;2019:8182195. https://doi.org/10.1155/2019/8182195.
60. Ho YY, Nakato J, Mizushige T, Kanamoto R, Tanida M, Akiduki S, Ohinata K. l-Ornithine stimulates growth hormone release in a manner dependent on the ghrelin system. Food Funct. 2017;8(6):2110–2114. https://doi.org/10.1039/c7fo00309a.
61. Le Bricon T, Cynober L, Baracos VE. Ornithine alpha-ketoglutarate limits muscle protein breakdown without stimulating tumor growth in rats bearing Yoshida ascites hepatoma. Metabolism. 1994;43(7):899–905. https://doi.org/10.1016/0026-0495(94)90274-7.
62. Le Bricon T, Cynober L, Field CJ, Baracos VE. Supplemental nutrition with ornithine alpha-ketoglutarate in rats with cancer-associated cachexia: surgical treatment of the tumor improves efficacy of nutritional support. J Nutr. 1995;125(12):2999–3010. https://doi.org/10.1093/jn/125.12.2999.
63. Myazin RG. A study on the efficacy and safety of L-ornithine-L-aspartate in the treatment of chronic liver diseases complicated by the development of hyperammonemia and sarcopenia: results of a clinical trial. Therapy. 2024;10(8 Suppl.):223. (In Russ.) Available at: https://rnmot.org/video/repository/sbornik_tezisov_fin_terapiya_nkt-tezis_2024_2dc7b450.pdf.
Review
For citations:
Okovityi SV, Nadinskaia MY, Maevskaya MV, Gladkov OA, Vasenina EE, Grechishnikova VR, Deeva TA, Zharkova MS, Osipenko MF, Prashnova MK, Prikhodko VA, Raikhelson KL. Materials of the Expert Council “Ornithine in Oncological Practice”. Meditsinskiy sovet = Medical Council. 2025;(8):8-16. (In Russ.) https://doi.org/10.21518/ms2025-237
Views:
149
Email this article 